Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150336 | 1.00 | KMT2A (0.69) | KMT2AMEN1L3MBTL1ALDH1A1PKM | |
| SCHEMBL7154807 | 1.00 | KMT2A (0.69) | KMT2AMEN1L3MBTL1ALDH1A1PKM | |
| SCHEMBL12930889 | 1.00 | KMT2A (0.69) | KMT2AMEN1L3MBTL1ALDH1A1PKM | |
| SCHEMBL7150056 | 1.00 | KMT2A (0.69) | KMT2AMEN1L3MBTL1ALDH1A1PKM | |
| SCHEMBL16308901 | 1.00 | KMT2A (0.69) | KMT2AMEN1L3MBTL1ALDH1A1PKM | |
| SCHEMBL24236918 | 1.00 | KMT2A (0.69) | KMT2AMEN1L3MBTL1ALDH1A1PKM | |
| SCHEMBL7155441 | 0.91 | KMT2A (0.69) | KMT2AMEN1L3MBTL1ALDH1A1PKM | |
| SCHEMBL7148921 | 0.89 | KMT2A (0.67) | KMT2AMEN1L3MBTL1ALDH1A1PKM | |
| SCHEMBL7153103 | 0.89 | KMT2A (0.67) | KMT2AMEN1L3MBTL1ALDH1A1PKM | |
| SCHEMBL10544363 | 0.89 | L3MBTL1 (0.64) | KMT2AMEN1L3MBTL1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300411-B1 | NOVEL DISACCHARIDES WITH ANTI-ARTHRITIC ACTION | BIOIBERICA (ES) | 2006-08-09 | — | — | EP | disclosed |
| US-6680304-B2 | GLUCOSAMINE DERIVATIVE; ANTIINFLAMMATORY, ANTIARTHRITIC, AND ANTICOAGULANT AGENTS | BIOIBERICA, S.A. (ES) | 2004-01-20 | — | — | US | disclosed |
| US-20030181400-A1 | Novel disaccharides with anti-arthrosic properties | BIOIBERICA, S.A. (ES) | 2003-09-25 | — | — | US | disclosed |
| EP-1300411-A1 | NOVEL DISACCHARIDES WITH ANTI-ARTHRITIC ACTION | BIOIBERICA, S.A. (ES) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181400-A1 | Novel disaccharides with anti-arthrosic properties | CA4, HLA-DRB1, CHIA | KMT2A 4029/4885MEN1 2593/4885L3MBTL1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.